论文部分内容阅读
目的：了解急性ST段抬高心梗患者接受瑞替普酶溶栓治疗的临床效果。方法随机抽取本院近年来收治应用瑞替普酶（rPA）溶栓治疗的急性ST段抬高心梗（STEMI）患者89例，设为观察组，另随机抽取本院同期应用重组链激酶治疗的STEMI患者75例，设为对照组。对比两组患者临床治疗效果。结果观察组血管再通率为79.8%高于对照组54.7%，1周内再闭塞率低于对照组，差异有统计学意义（P＜0.05）；观察组出现并发症概率为6.7%，显著低于对照组22.6%，差异有统计学意义（P＜0.05）。结论对急性S T段抬高心梗患者应用瑞替普酶溶栓治疗能够取得令人满意的临床疗效，且出血性并发症少，不会对疗程和患者生活质量造成影响,值得临床推广。“,”Objective: To investigate the clinical effect of reteplase thrombolytic therapy in patients with acute ST- elevation myocardial infarction received. Methods: The patients of STEMI were randomly divided into reteplase group(observation group ,n=89) and recombinant streptokinase group(control group ,n=75), Compared two groups of patients with clinical curative effect. Results: after the treatment, the observation group of vascular recanalization rate was 79.8% higher than that of the control group 54.7%, 1 weeks re occlusion rate lower than that of the control group (P < 0.05);The probability of complications was 6.7% in the observation group,Significantly lower than the control group 22.6% (P < 0.05). Conclusion: Reteplase thrombolytic therapy Can obtain satisfactory curative effectand And less bleeding complications ,the treatment does not appear serious adverse reactions, wil not affect the course of treatment and quality of life of patients, is worthy of clinical promotion.